Cargando…

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy

The effect of deferasirox dosing tailored for iron burden and iron loading based on liver iron concentration (LIC) was assessed over 1 year in less versus more heavily iron-overloaded patients in a substudy of the Evaluation of Patients’ Iron Chelation with Exjade®. Deferasirox starting dose was 10–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porter, J. B., Elalfy, M. S., Taher, A. T., Aydinok, Y., Chan, L. L., Lee, S.-H., Sutcharitchan, P., Habr, D., Martin, N., El-Beshlawy, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542426/ https://www.ncbi.nlm.nih.gov/pubmed/23086508 http://dx.doi.org/10.1007/s00277-012-1588-x

Ejemplares similares

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2011)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
por: Taher, Ali, et al.
Publicado: (2011)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
por: Porter, John B, et al.
Publicado: (2011)

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration
por: St Pierre, Tim G, et al.
Publicado: (2014)

5613049 THE DIAGNOSTIC ACCURACY AND REPEATABILITY OF AN ARTIFICIAL INTELLIGENCE BASED SYSTEM TO OBTAIN AUTOMATED LIVER IRON CONCENTRATION MEASUREMENTS USING MAGNETIC RESONANCE IMAGING.
por: St Pierre, T.G., et al.
Publicado: (2023)

P1505: USING ARTIFICIAL INTELLIGENCE NEURAL NETWORKS TO OBTAIN AUTOMATED LIVER IRON CONCENTRATION MEASUREMENTS USING MAGNETIC RESONANCE IMAGING – A MULTI-SCANNER VALIDATION STUDY
por: St Pierre, T., et al.
Publicado: (2022)

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2018)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Worldwide survey of T2* cardiovascular magnetic resonance in Thalassaemia
por: Carpenter, John-Paul, et al.
Publicado: (2011)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox
por: Palumbo, Giuseppe A., et al.
Publicado: (2021)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Effects of oral iron chelator deferasirox on human malignant lymphoma cells
por: Choi, Jong Gwon, et al.
Publicado: (2012)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016)

Evaluation of Liver Iron Content by Magnetic Resonance Imaging in Children with Acute Lymphoblastic Leukemia after Cessation of Treatment
por: Acar, Sezer, et al.
Publicado: (2020)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2020)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

The role of cardiovascular magnetic resonance in women with suspected CAD: a CE-MARC substudy
por: Greenwood, John P, et al.
Publicado: (2012)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
por: Kim, Dae Sik, et al.
Publicado: (2016)

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease
por: Raj, Ashok, et al.
Publicado: (2022)

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3s7kkngf9d4vqaanfr0t0di0e0